Actively Recruiting
Feasibility of a Multi-omics Platform for Hematological Malignancies
Led by Azienda Ospedaliero-Universitaria di Parma · Updated on 2026-03-03
1040
Participants Needed
1
Research Sites
N/A
Total Duration
On this page
AI-Summary
What this Trial Is About
Researchers are investigating a wide range of hematological malignancies, including acute and chronic leukemias, myeloproliferative and lymphoproliferative disorders, and myelodysplastic conditions, as classified in the WHO 2022 guidelines. This collaborative biological study involves multiple Italian hematology centers and aims to explore disease characteristics and potential biomarkers using advanced multi-omics techniques. Both retrospective and prospective samples will be analyzed to better understand these blood cancers and related disorders. The study involves collecting bone marrow or peripheral blood samples, lymph node or tissue biopsies with metastatic involvement, and other biological fluids like cerebrospinal fluid and pathological pleural effusion from patients during routine diagnostic or relapse evaluations. Retrospective patients with previously stored frozen samples will also be included. Multi-omics analyses such as next-generation sequencing, bulk and single-cell transcriptomics, and phosphoproteomics will be performed, alongside functional drug testing on cultured malignant cells exposed to a library of 300 drugs at various concentrations over 72 hours. Participants will provide biological samples either retrospectively or prospectively during their regular diagnostic workups. These samples will be sent fresh or frozen to the central laboratory for detailed molecular and functional testing. The study will measure multi-omics features to identify disease biomarkers and assess the anti-cancer activity of bioactive compounds for personalized pharmacotyping. The research team will monitor these outcomes at baseline. The study is planned to continue until March 2030, with patient involvement focused on sample collection and laboratory analyses without altering standard care.
CONDITIONS
Brief Title
Feasibility of a Multi-omics Platform for Hematological Malignancies
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Patient aged > 2 years old
- Previously diagnosed with hematological malignancies (retrospective study)
- Clinical suspicion of hematological malignancies requiring diagnostic assessment using bone marrow, peripheral blood, lymph node or tissue biopsies, or other biological fluids (prospective study)
- Clinical suspicion of relapsed or refractory onco-hematological disorders requiring diagnostic assessment using relevant biological samples
- Blastic transformation from a chronic condition or suspicion of relapsed/refractory hematological disease requiring diagnostic assessment using appropriate samples
You will not qualify if you...
- Age under 2 years old
- Patient without a diagnosis of hematological malignancy
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Your Study Journey
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
Duration - Varies based on diagnostic schedule
Participants provide biological samples during routine diagnostic or relapse investigations for multi-omics and functional analyses.
Samples collected during routine diagnostic visits
Trial Site Locations
Total: 1 location
1
University of Parma
Parma, PR, Italy, 43126
Actively Recruiting
Research Team
G
Giovanni Roti, Associate Professor
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SINGLE_GROUP
Primary Purpose
BASIC_SCIENCE
Number of Arms
1
Similar Trials
Frequently Asked Questions
Have more questions? Get in touch with our team for quick support
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here